Clover Health Investments Corp CLOV shares are trading lower in Monday's after-hours session after the company reported financial results and reaffirmed full-year guidance.
Clover Health said second-quarter revenue more than doubled year-over-year to $846.7 million, which beat the estimate of $814.62 million, according to data from Benzinga Pro. The company reported a net loss of $(104.2) million.
Lives under management climbed to approximately 255,000 during the second quarter, up from about 129,000 year-over-year. The company highlighted its insurance medical care ratio of 92.1%, showing significant improvement year-over-year.
"Our focus on building a sustainable, intelligent growth engine has led to a reduction in MCRs and improvement in operational efficiencies, which we believe is the foundation of our progress toward profitability," said Vivek Garipalli, CEO of Clover Health.
Full-year revenue is expected to be between $3 billion and $3.4 billion versus the estimate of $3.31 billion. Insurance memberships are expected to average between 84,000 and 85,000. Insurance MCR is expected to be in a range of 95% to 99%.
See Also: Novavax Q2 Results Trail Street Expectations, Slashes FY22 Outlook By 50%
CLOV Price Action: Clover Health has a 52-week high of $4.11 and a 52-week low of $1.95.
The stock was down 8.82% in after-hours at $3.10 at press time.
Photo: fernando zhiminaicela from Pixabay.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.